Swedish Orphan Biovitrum AB (publ) - ESG Rating & Company Profile powered by AI
This dashboard includes a questions and answers table about Swedish Orphan Biovitrum AB (publ). This Disclosure rating covers seventeen United Nations Sustainable Development Goals including: 'Zero Hunger', 'Climate Action' and 'Life on Land'. The webpage of Swedish Orphan Biovitrum AB (publ) is prepared by All Street Sevva using leading machine learning.
Swedish Orphan Biovitrum AB (publ) in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 0.0, social score of 4.6 and governance score of 4.0.
2.9
Low ImpactEnvironmental
Social
Governance
![Detailed ESG Breakdown](/resource/detailed-esg.png?ts=1725478325797)
Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
1336 | Sensorion SA | 3.0 | Medium |
1353 | Swedish Orphan Biovitrum AB (publ) | 2.9 | Medium |
1353 | Caribou Biosciences Inc | 2.9 | Medium |
1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |
![Peer Companies Benchmark](/resource/peer-benchmark-2.png?ts=1725478325797)
Frequently Asked Questions
Does Swedish Orphan Biovitrum AB (publ) have an accelerator or VC vehicle to help deliver innovation?
Does Swedish Orphan Biovitrum AB (publ) disclose current and historical energy intensity?
Does Swedish Orphan Biovitrum AB (publ) report the average age of the workforce?
Does Swedish Orphan Biovitrum AB (publ) reference operational or capital allocation in relation to climate change?
Does Swedish Orphan Biovitrum AB (publ) disclose its ethnicity pay gap?
Does Swedish Orphan Biovitrum AB (publ) disclose cybersecurity risks?
Does Swedish Orphan Biovitrum AB (publ) offer flexible work?
Does Swedish Orphan Biovitrum AB (publ) have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Swedish Orphan Biovitrum AB (publ) disclose the number of employees in R&D functions?
Does Swedish Orphan Biovitrum AB (publ) conduct supply chain audits?
Does Swedish Orphan Biovitrum AB (publ) disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Swedish Orphan Biovitrum AB (publ) conduct 360 degree staff reviews?
Does Swedish Orphan Biovitrum AB (publ) disclose the individual responsible for D&I?
Does Swedish Orphan Biovitrum AB (publ) disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Swedish Orphan Biovitrum AB (publ) disclose current and / or historical scope 2 emissions?
Does Swedish Orphan Biovitrum AB (publ) disclose water use targets?
Does Swedish Orphan Biovitrum AB (publ) have careers partnerships with academic institutions?
Did Swedish Orphan Biovitrum AB (publ) have a product recall in the last two years?
Does Swedish Orphan Biovitrum AB (publ) disclose incidents of discrimination?
Does Swedish Orphan Biovitrum AB (publ) allow for Work Councils/Collective Agreements to be formed?
Has Swedish Orphan Biovitrum AB (publ) issued a profit warning in the past 24 months?
Does Swedish Orphan Biovitrum AB (publ) disclose parental leave metrics?
Does Swedish Orphan Biovitrum AB (publ) disclose climate scenario or pathway analysis?
Does Swedish Orphan Biovitrum AB (publ) disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Swedish Orphan Biovitrum AB (publ) disclose the pay ratio of women to men?
Does Swedish Orphan Biovitrum AB (publ) support suppliers with sustainability related research and development?
Does Swedish Orphan Biovitrum AB (publ) disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Swedish Orphan Biovitrum AB (publ) reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Swedish Orphan Biovitrum AB (publ) involved in embryonic stem cell research?
Does Swedish Orphan Biovitrum AB (publ) disclose GHG and Air Emissions intensity?
Does Swedish Orphan Biovitrum AB (publ) disclose its waste policy?
Does Swedish Orphan Biovitrum AB (publ) report according to TCFD requirements?
Does Swedish Orphan Biovitrum AB (publ) disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Swedish Orphan Biovitrum AB (publ) disclose energy use targets?
Does Swedish Orphan Biovitrum AB (publ) disclose its Renewable Energy targets?
![Only Subscribers](/resource/reload.png)
Are emissions metrics verified by STBi?
![Only Subscribers](/resource/reload.png)
Does Swedish Orphan Biovitrum AB (publ) have a policy relating to cyber security?
Have a different question?
Potential Risks for Swedish Orphan Biovitrum AB (publ)
These potential risks are based on the size, segment and geographies of the company.
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.